Catalyst Pharmaceuticals (NASDAQ:CPRX) Receives “Overweight” Rating from Stephens

Catalyst Pharmaceuticals (NASDAQ:CPRX)‘s stock had its “overweight” rating reaffirmed by research analysts at Stephens in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $33.00 price target on the biopharmaceutical company’s stock. Stephens’ price target suggests a potential upside of 44.14% from the company’s current price.

A number of other equities research analysts also recently weighed in on the stock. StockNews.com downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Truist Financial upped their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Bank of America reissued a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Finally, HC Wainwright upped their target price on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Trading Up 11.2 %

Shares of CPRX stock opened at $22.90 on Thursday. Catalyst Pharmaceuticals has a 12 month low of $14.16 and a 12 month high of $24.64. The company has a market capitalization of $2.73 billion, a P/E ratio of 19.53, a P/E/G ratio of 3.31 and a beta of 0.80. The stock has a 50 day moving average of $22.21 and a two-hundred day moving average of $21.40.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 50,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CPRX. Armis Advisers LLC acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at $306,000. Mackenzie Financial Corp boosted its stake in shares of Catalyst Pharmaceuticals by 132.9% in the 4th quarter. Mackenzie Financial Corp now owns 34,531 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 19,705 shares during the last quarter. Castlekeep Investment Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth approximately $1,775,000. Neo Ivy Capital Management bought a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth approximately $744,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Catalyst Pharmaceuticals by 11.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 263,905 shares of the biopharmaceutical company’s stock valued at $5,508,000 after buying an additional 27,683 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.